Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.

@article{Aldecoa2019TargetedSA,
  title={Targeted sequencing and molecular profiling of a papillary and cribriform clear cell intrahepatic cholangiocarcinoma reveals absence of selectable mutations.},
  author={Iban Aldecoa and Carla Montironi and Guillermo Madrigal Vargas and Diego Alcaraz Nunes and Rosa Miquel and M{\'i}riam Cuatrecasas},
  journal={Gastroenterologia y hepatologia},
  year={2019},
  volume={42 6},
  pages={
          374-375
        }
}

References

SHOWING 1-5 OF 5 REFERENCES
Molecular characteristics of biliary tract cancer.
TLDR
A comprehensive review of biliary tract cancer genomics and their clinical implications is presented, finding alterations in genes in the EGFR-MAPK-PI3K pathway are seen most often and FGF and IDH pathway alterations are potential targets for therapeutic agents.
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
TLDR
RNA- and exome-sequencing technologies revealed the presence of recurrent novel fusion events (FGFR2 and ROS1 fusions) and somatic mutations in metabolic (IDH1/2) and chromatin-remodeling genes (ARID1A, BAP1) and known mutations in KRAS/BRAF/EGFR and 11q13 high-level amplification have contributed to a better understanding of the landscape of molecular alterations in iCCA.
Clear cell papillary cholangiocarcinoma: a case report with review of literature.
TLDR
Clinical, histopathological, and immunohistochemical findings of one such rare case in a 66-year-old gentleman who was incidentally detected to have an intrahepatic tumor at routine ultrasound examination are described.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
TLDR
The results of this study show for the first time that isocitrate dehydrogenase 1 and 2 genes are mutated in cholangiocarcinoma, which identifies a new potential target for genotype-directed therapeutic trials and may represent a potential biomarker for earlier detection of cholangsiocARCinoma in a subset of cases.
CD56 (NCAM) expression in pancreatic carcinoma and the surrounding pancreatic tissue.
TLDR
It is suggested that CD56 expression is degenerative process in pancreatic tissue with chronic inflammation, and that examination ofCD56 expression may be helpful in the differentiation of atypical degenerative ducts from cancerous ducts.